OTHER FUNCTIONS ENUMERAL "PHASE I, TOPIC 309, DETECTION OF MULTIPLE ANALYTES FRO

其他功能枚举“第一阶段，主题 309，多种分析物的检测

• 批准号: 8566228
• 金额: $ 19.98万
• 依托单位: ENUMERAL BIOMEDICAL CORPORATION
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-28 至 2013-06-27
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8566228
• 关键词: Affect; Automation; Biological Assay; Biopsy; Biopsy Specimen; Cause of Death; Cells; Clinical; Colon Carcinoma; Complex; Detection; Diagnosis; Diagnostic; Disease; Fine needle aspiration biopsy; Gene Expression; Goals; Harvest; Liquid substance; Malignant Neoplasms; Measurement; Measures; Membrane Proteins; Patients; Performance; Phase; Process; Sampling; Stratification; System; Technology; Testing; Tissue Sample; Tissues; base; design; mortality; prototype; reagent testing; tumor progression

Cancer is a leading cause of death that affects millions of lives across the world. It is a complex disease that is likely to require multifactorial measurements for earlier and more accurate diagnosis and patient stratification. Tissue biopsies and fine needle aspirates are commonly collected clinically, but existing multi-analyte technology platforms are ill-equipped to derive meaningful information from single samples. The goal of this proposal is to characterize Enumeral¿s technology for the measurement of multiple analytes on clinical samples and to generate a design for an automated prototype system to be used in Phase II. Enumeral¿s platform is ideally suited for the measurement of small samples, as it can accept and analyze cell samples of any size from any tissue in the body. The system will be characterized with commercially available reagents and tested on biopsy samples to measure secreted proteins, surface markers, and gene expression. With the mortality associated with cancer and the sheer volume of clinical samples taken on an annual basis, the advancement of technologies for the analysis of small tissue samples has the potential to advance the understanding of cancer progression and open new doors for diagnostic and treatment paradigms.

癌症是影响全世界数百万人生命的主要死亡原因。它是一种复杂的疾病，可能需要多因素测量，以便更早和更准确地诊断和患者分层。组织活检和细针抽吸通常在临床上收集，但现有的多分析物技术平台不足以从单个样品中获得有意义的信息。 该提案的目标是描述Enumeric用于测量临床样本中多种分析物的技术，并为第二阶段使用的自动化原型系统设计。Enumeric？的平台非常适合测量小样本，因为它可以接受和分析来自体内任何组织的任何大小的细胞样本。该系统将使用市售试剂进行表征，并在活检样本上进行测试，以测量分泌蛋白、表面标志物和基因表达。 随着与癌症相关的死亡率和每年采集的大量临床样本，小组织样本分析技术的进步有可能促进对癌症进展的理解，并为诊断和治疗模式打开新的大门。